Merck looks to modest HIV business as a $5B underdog...underdog???

With Keytruda's patent cliff looming. (2027) I believe...

Merck has to to find WAYS to shore up its business, and it is betting that HIV will be one of those that assist in that endeavor.

Speaking of connecting the dots...don't We have a kind of HIV drug...underdog???